-DOCSTART- -X- O
Influenza -X- _ O
is -X- _ O
a -X- _ O
perennial -X- _ O
problem -X- _ O
affecting -X- _ O
millions -X- _ B-Patient
of -X- _ I-Patient
people -X- _ I-Patient
annually -X- _ I-Patient
with -X- _ I-Patient
the -X- _ I-Patient
everpresent -X- _ I-Patient
threat -X- _ I-Patient
of -X- _ I-Patient
devastating -X- _ I-Patient
pandemics. -X- _ I-Patient
Active -X- _ B-Intervention
prophylaxis -X- _ I-Intervention
by -X- _ I-Intervention
vaccination -X- _ I-Intervention
against -X- _ I-Intervention
influenza -X- _ I-Intervention
virus -X- _ I-Intervention
is -X- _ I-Intervention
currently -X- _ I-Intervention
the -X- _ I-Intervention
main -X- _ I-Intervention
countermeasure -X- _ I-Intervention
supplemented -X- _ I-Intervention
with -X- _ I-Intervention
antivirals. -X- _ I-Intervention
However -X- _ O
, -X- _ O
disadvantages -X- _ O
of -X- _ O
this -X- _ O
strategy -X- _ O
include -X- _ O
the -X- _ O
impact -X- _ O
of -X- _ O
antigenic -X- _ O
drift -X- _ O
, -X- _ O
necessitating -X- _ O
constant -X- _ O
updating -X- _ O
of -X- _ O
vaccine -X- _ O
strain -X- _ O
composition -X- _ O
, -X- _ O
and -X- _ O
emerging -X- _ O
antiviral -X- _ O
drug -X- _ O
resistance. -X- _ O
The -X- _ O
development -X- _ O
of -X- _ O
other -X- _ O
options -X- _ O
for -X- _ O
influenza -X- _ O
prophylaxis -X- _ O
, -X- _ O
particularly -X- _ O
with -X- _ O
broad -X- _ O
acting -X- _ O
agents -X- _ O
able -X- _ O
to -X- _ O
provide -X- _ O
protection -X- _ O
in -X- _ O
the -X- _ O
period -X- _ O
between -X- _ O
the -X- _ O
onset -X- _ O
of -X- _ O
a -X- _ O
pandemic -X- _ O
and -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
a -X- _ O
strain -X- _ O
specific -X- _ O
vaccine -X- _ O
, -X- _ O
is -X- _ O
of -X- _ O
great -X- _ O
interest. -X- _ O
Exploitation -X- _ O
of -X- _ O
broad-spectrum -X- _ B-Intervention
mediators -X- _ I-Intervention
could -X- _ I-Intervention
provide -X- _ I-Intervention
barricade -X- _ I-Intervention
protection -X- _ I-Intervention
in -X- _ I-Intervention
the -X- _ I-Intervention
early -X- _ I-Intervention
critical -X- _ I-Intervention
phase -X- _ I-Intervention
of -X- _ I-Intervention
influenza -X- _ I-Intervention
virus -X- _ I-Intervention
outbreaks. -X- _ I-Intervention
Passive -X- _ B-Intervention
immunity -X- _ I-Intervention
has -X- _ I-Intervention
the -X- _ I-Intervention
potential -X- _ I-Intervention
to -X- _ I-Intervention
provide -X- _ I-Intervention
immediate -X- _ I-Intervention
antiviral -X- _ I-Intervention
effects -X- _ I-Intervention
, -X- _ I-Intervention
inhibiting -X- _ I-Intervention
virus -X- _ I-Intervention
replication -X- _ I-Intervention
, -X- _ I-Intervention
reducing -X- _ I-Intervention
virus -X- _ I-Intervention
shedding -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
thereby -X- _ I-Intervention
protecting -X- _ I-Intervention
vulnerable -X- _ I-Intervention
populations -X- _ I-Intervention
in -X- _ I-Intervention
the -X- _ I-Intervention
event -X- _ I-Intervention
of -X- _ I-Intervention
an -X- _ I-Intervention
impending -X- _ I-Intervention
influenza -X- _ I-Intervention
pandemic. -X- _ I-Intervention
Here -X- _ O
, -X- _ O
we -X- _ O
review -X- _ O
passive -X- _ O
broad-spectrum -X- _ O
influenza -X- _ O
prophylaxis -X- _ O
options -X- _ O
with -X- _ O
a -X- _ O
focus -X- _ O
on -X- _ O
harnessing -X- _ O
natural -X- _ B-Outcome
host -X- _ I-Outcome
defenses -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
interferons -X- _ I-Outcome
and -X- _ I-Outcome
antibodies -X- _ I-Outcome
. -X- _ O

